PIA
KERX

Piedmont Investment Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Piedmont Investment Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,641
Closed -$6K – 2885
2018
Q2 		$6K Buy
+1,641
New +$7.99K ﹤0.01% 2080
2015
Q4 		– Sell
-41
Closed -$144 – 431
2015
Q3 		$144 Hold
41
– – ﹤0.01% 405
2015
Q2 		$409 Buy
+41
New +$440 ﹤0.01% 407

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Piedmont Investment Advisors's KERX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 1,641 shares — an estimated $6K sold.

Piedmont Investment Advisors first reported a position in KERX in Q2 2015 and held it in 3 quarters. The position peaked at $6K in Q2 2018. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,641 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $6K.
  • Piedmont Investment Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 3 quarters.
  • Piedmont Investment Advisors's Keryx Biopharmaceuticals Inc position peaked at $6K in Q2 2018.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.